The role of the substantia nigra pars compacta in regulating sleep patterns in rats

PLoS ONE

Volumn 2, Issue 6, 2007, Pages

  Lima, Marcelo M S ^a   Andersen, Monica L ^a   Reksidler, Angela B ^b   Vital, Maria A B F ^b   Tufik, Sergio ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINE 3 MONOOXYGENASE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; LIGHT DARK CYCLE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REM SLEEP; SLEEP PATTERN; SLEEP WAKING CYCLE; SLOW WAVE SLEEP; SUBSTANTIA NIGRA; ANIMAL; CIRCADIAN RHYTHM; CYTOLOGY; DRUG EFFECT; ELECTROPHYSIOLOGY; ENZYME IMMUNOASSAY; METABOLISM; NERVE CELL; PHYSIOLOGY; SLEEP; WAKEFULNESS; WISTAR RAT;

RATTUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CIRCADIAN RHYTHM; ELECTROPHYSIOLOGY; IMMUNOENZYME TECHNIQUES; MALE; NEURONS; RATS; RATS, WISTAR; SLEEP; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; WAKEFULNESS;

EID: 36849078759     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000513     Document Type: Article

References (32)

1. Adler CH (2005) Nonmotor complications in Parkinson's disease. Mov Disord 20: S23-S29.
2. Gagnon JF, Bedard MA, Fantini ML, Petit D, Panisset M, et al. (2002) REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology. 59: 585-589.
3. Hobson D, Lang A, Wayne MW, Razmy A, Rivest J, et al. (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson Disease. A survey by the Canadian Movement Disorder Group. JAMA 287: 455-463.
4. Sandyk R (1997) Treatment with weak electromagnetic fields restores dream recall in a parkinsonian patient. Int J Neurosci 90: 75-86.
5. Hobson JA, Pace-Schott EF, Stickgold R, Kahn D (1998) To dream or not to dream? Relevant data from new neuroimaging and electrophysiological studies, Curr Opin Neurobiol. 8: 239-244.
6. Poewe W, Högl B (2000) Parkinson's disease and sleep. Curr Opin Neurol 13: 423-426.
7. Rye DB, Jankovic J (2002) Emerging views of dopamine in modulation sleep/ wake state from an unlikely source: PD. Neurology 58: 341-346.
8. Wauquier A (1995) Pharmacology of the catecholaminergic system. The Pharmacology of Sleep. Handbook of Experimental Pharmacology. Berlin, Heidelberg: New York.
9. Marsden CA (2006) Dopamine: the rewarding years. British Journal of Pharmacology 147: S136-S144.
10. Larsen JP, Tandberg E (2001) Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 15: 267-275.
11. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, et al. (2002) Parkinson's disease and sleepiness: an integral part of PD. Neurology 58: 1019-1024.
12. Tufik S, Lindsey CJ, Carlini EA (1978) Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain? Pharmacology 16: 98-105.
13. Tufik S (1981) Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation. Psychopharmacology (Berl) 72: 257-260.
14. Nunes Jr GP, Tufik S, Nobrega JN (1994) Autoradiographic analysis of D1 and D2 dopaminergic receptors in rat brain after paradoxical sleep deprivation. Brain Research Bulletin 34: 453-456.
15. Dzirasa K, Ribeiro S, Costa R, Santos L, Lin S-C, et al. (2006) Dopaminergic Control of Sleep-Wake States. The Journal of Neuroscience 26: 1-13.
16. Dahan L, Astier B, Vautrelle N, Urbain N, Kocsis B, et al. (2006) Prominent Burst of Firing Neurons in the Ventral Tegmental Area during Paradoxical Sleep. Neuropsychopharmacology 1-10.
17. Chiba K, Trevor A, Castagnoli N Jr (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574-578.
18. Beal MF (2001) Experimental models of Parkinson's disease. Nat Rev Neurosci 2: 325-334.
19. Lima MMS, Reksidler AB, Zanata SM, Machado HB, Tufik S, et al. (2006) Different parkinsonism models produce a time dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101: 117-125.
20. Reksidler AB, Lima MMS, Zanata SM, Machado HB, Da Cunha C, et al. (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. European Journal of Pharmacology 560: 163-175.
21. Paxinos G, Watson C (2005) The Rat Brain in Stereotaxic Coordinates. 5th ed. San Diego: Academic Press.
22. Jouvet M (1967) The states of sleep. Sci Am 216: 62-68.
23. Timo-Iaria C, Negrao N, Schmidek WR, Hoshino K, Lobato de Menezes CE, et al. (1970) Phases and states of sleep in the rat. Physiol Behav 5: 1057-1062.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin protein reagent. J Bio Chem 193: 265-275.
25. Monti JM, Monti D (2007) The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 11: 113-133.
26. Jones BE, Bobillier P, Jouvet M (1969) Effect of destruction of neurons containing catecholamines of the mesencephalon on the sleep-wake cycle in cats. C R Seances Soc Biol Fil 163: 176-180.
27. Jones BE, Bobillier P, Pin C, Jouvet M (1973) The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat. Brain Res 58: 157-177.
28. Lev N, Melamed E, Offen D (2003) Apoptosis and Parkinson's disease. Prog in Neuro-Psychopharmacol & Biol Psych 27: 245-250.
29. Green DR (2005) Apoptotic Pathways: Ten Minutes to Dead. Cell 121: 671-674.
30. Pungor K, Papp M, Kekesi K, Juhasz G (1990) A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. Brain Res 525: 310-314.
31. Ulivelli M, Rossi S, Lombardi C, Bartalini S, Rocchi R, et al. (2002) Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 58: 462-465.
32. De Cock VC, Vidailhet M, Leu S, Teixeira A, Apartis E, et al. (2007) Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 130: 450-456.